iNtRON Biotechnology Inc
KOSDAQ:048530
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 915
5 690
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
i
|
iNtRON Biotechnology Inc
KOSDAQ:048530
|
109.7B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.3B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.4B USD |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
iNtRON Biotechnology Inc
Glance View
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for iNtRON Biotechnology Inc is -113.2%, which is below its 3-year median of -64.2%.
Over the last 3 years, iNtRON Biotechnology Inc’s Net Margin has decreased from 60.1% to -113.2%. During this period, it reached a low of -115.5% on Jun 30, 2025 and a high of 60.1% on Aug 30, 2022.